{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:47:26Z","timestamp":1775058446658,"version":"3.50.1"},"reference-count":89,"publisher":"Societatea Romana de Morfologie","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:p>Thyroid malignancy represents the most common type of endocrine cancer, with an increasing incidence all over the world, including an increasing rate of detection among younger adults, 90% to 95% of all cases being non-medullary types. Poorly differentiated thyroid cancer, accounting 1% to 5% of all thyroid malignancies, is a less understood neoplasm compared to the other more frequent and better described thyroid cancers, associating various histological patterns that might bring pitfalls of diagnosis in everyday practice. We aimed to provide an updated analysis in the field of poorly differentiated thyroid carcinoma, based on a multimodal approach, including emergent biomarkers. The current data offers a robust framework for elucidating the biology of poorly differenced thyroid malignancy and further on, it provides the basis for a multilayered therapeutic approach. Emergent biomarkers might be detected from cytological analysis based on fine-needle aspiration or blood assays as cell-free deoxyribonucleic acid (cfDNA), but the most important remains the identification of the molecular and genetic constellation in terms of analyzing RAS, telomerase reverse transcriptase (TERT), B-Raf proto-oncogene, serine\/threonine kinase (BRAF), tumor protein p53 (TP53), phosphatase and tensin homolog (PTEN), copy number alterations (CNA) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) profile, which serve as prognostic markers and pointers of anti-cancer medical therapy. Overall, despite recent advances in multimodal management, the prognostic remains severe. The issue is ongoing, and we expect a massive expansion within the following years, across a guideline-based, as well as a personalized decision.<\/jats:p>","DOI":"10.47162\/rjme.66.3.01","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:41:45Z","timestamp":1768819305000},"page":"431-442","source":"Crossref","is-referenced-by-count":1,"title":["Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis)"],"prefix":"10.47162","volume":"66","author":[{"name":"Doctoral School, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Radiology and Medical Imaging, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania; Department of Thoracic Surgery, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Costachescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Ionovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Occupational Medicine, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana Cristina","family":"Terzea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathology, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania; Oncoteam Diagnostics, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florina","family":"Vasilescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Oncoteam Diagnostics, Bucharest, Romania; Department of Pathology, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucian-George","family":"Eftimie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathology, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra-Ioana","family":"Trandafir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Clinical Endocrinology V, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Maria","family":"Gheorghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Clinical Endocrinology V, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana-Claudia","family":"Sima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Clinical Endocrinology V, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudiu","family":"Nistor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Thoracic Surgery, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania; Discipline of Thoracic Surgery II, Department 4 \u2013 Cardio-Thoracic Pathology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Carsote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Clinical Endocrinology V, C.I. Parhon National Institute of Endocrinology, Bucharest, Romania; Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26736","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] Abrosimov AY, Kuryshev AA. [High-grade encapsulated follicular cell thyroid carcinomas]. Arkh Patol, 2024, 86(5):60-64. https:\/\/doi.org\/10.17116\/patol20248605160","DOI":"10.17116\/patol20248605160"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Hekimsoy \u0130, Ertan Y, Serin G, Karabulut AK, \u00d6zbek SS. Comparison of ultrasound findings of papillary thyroid carcinoma subtypes based on the 2022 WHO Classification of thyroid neoplasms. Front Endocrinol (Lausanne), 2024, 15:1434787. https:\/\/doi.org\/10.3389\/fendo.2024.1434787","DOI":"10.3389\/fendo.2024.1434787"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Srivastava A, Skopelitou D, Miao B, Giagiobbe S, Paramasivam N, Kumar A, Diquigiovanni C, Bonora E, Bandapalli OR, F\u00f6rsti A, Hemminki K. Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing. Eur J Endocrinol, 2025, 192(4):398-407. https:\/\/doi.org\/10.1093\/ejendo\/lvaf045","DOI":"10.1093\/ejendo\/lvaf045"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] Boudina M, Zisimopoulou E, Xirou P, Chrisoulidou A. Aggressive types of malignant thyroid neoplasms. J Clin Med, 2024, 13(20):6119. https:\/\/doi.org\/10.3390\/jcm13206119","DOI":"10.3390\/jcm13206119"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Juhlin CC. The road ahead: a brief guide to navigating the 2022 WHO Classification of endocrine and neuroendocrine tumours. J Clin Pathol, 2024, 78(1):1-10. https:\/\/doi.org\/10.1136\/jcp-2023-209060","DOI":"10.1136\/jcp-2023-209060"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"[6] Goswami P, Patel T, Dave R, Singh G, Singh A, Kalonia T. WHO 2022 updates on follicular cell and C-cell derived thyroid neoplasm. J Med Life, 2024, 17(1):15-23. https:\/\/doi.org\/10.25122\/jml-2023-0270","DOI":"10.25122\/jml-2023-0270"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"[7] Patel N, Bavikar R, Lad YP, Singh M, Dharwadkar A, Viswanathan V. A comparison of the WHO 2004 and WHO 2017 thyroid tumor classifications. J Cancer Res Ther, 2024, 20(1):311-314. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1797_22","DOI":"10.4103\/jcrt.jcrt_1797_22"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"[8] Juhlin CC, Mete O, Baloch ZW. The 2022 WHO Classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer, 2022, 30(2):e220293. https:\/\/doi.org\/10.1530\/ERC-22-0293","DOI":"10.1530\/ERC-22-0293"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization Classification of thyroid tumors: a standardized diagnostic approach. Endocrinol Metab (Seoul), 2022, 37(5):703-718. https:\/\/doi.org\/10.3803\/EnM.2022.1553","DOI":"10.3803\/EnM.2022.1553"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Wong KS, Barletta JA. The new endocrine WHO Classification: what does this mean for thyroid cytology? Cancer Cytopathol, 2022, 130(9):658-662. https:\/\/doi.org\/10.1002\/cncy.22634","DOI":"10.1002\/cncy.22634"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Cameselle-Teijeiro JM. [Changes and perspectives in the new 2022 WHO Classification of thyroid neoplasms]. Rev Esp Patol, 2022, 55(3):145-148. https:\/\/doi.org\/10.1016\/j.patol.2022.06.001","DOI":"10.1016\/j.patol.2022.06.001"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Haq F, Bychkov A, Mete O, Jeon S, Jung CK. Identification of specific biomarkers for anaplastic thyroid carcinoma through spatial transcriptomic and immunohistochemical profiling. Endocr Pathol, 2025, 36(1):14. https:\/\/doi.org\/10.1007\/s12022-025-09858-z","DOI":"10.1007\/s12022-025-09858-z"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Ahn JH, Yi JW. Cell cycle and HIF-1 related gene expression alteration in thyroid cell lines under microgravity. Oncol Res, 2025, 33(8):1909-1931. https:\/\/doi.org\/10.32604\/or.2025.065847","DOI":"10.32604\/or.2025.065847"},{"key":"ref13","unstructured":"[14] Carsote M, Valea A, Dumitru N, Terzea D, Petrova E, Albu S, Buruiana A, Ghemigian A. Metastases in daily endocrine practice. Arch Balk Med Union, 2016, 51(4):478-482."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"[15] Hsu CW, Hsueh C, Lu YL, Hsu CJ, Wong RJ, Lin SF. Risk factors and outcomes of metastatic poorly differentiated thyroid carcinoma. World J Clin Cases, 2025, 13(25):105204. https:\/\/doi.org\/10.12998\/wjcc.v13.i25.105204","DOI":"10.12998\/wjcc.v13.i25.105204"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] Tang H, Tao Y, Zhang Y, Ling Y, Sheng Y, Yu L. Hydrogel-driven innovations for targeted delivery, immune modulation, and tissue repair in thyroid cancer therapy. Front Cell Dev Biol, 2025, 13:1608709. https:\/\/doi.org\/10.3389\/fcell.2025.1608709","DOI":"10.3389\/fcell.2025.1608709"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] An JJ, Choi MS, Yang C, Teng MS, van Gerwen M. Age-specific risk of second primary malignant neoplasm after radioactive iodine treatment for differentiated thyroid cancer. JAMA Otolaryngol Head Neck Surg, 2025, Aug 21:e252626. https:\/\/doi.org\/10.1001\/jamaoto.2025.2626","DOI":"10.1001\/jamaoto.2025.2626"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Odate T, Kondo T, Katoh R, Ito K, Ueno T, Yatabe Y, Mori T. Progression of follicular thyroid carcinomas to anaplastic thyroid carcinomas: molecular and clinicopathologic characteristics with comparison to papillary thyroid carcinoma-derived anaplastic thyroid carcinomas. Endocr Pathol, 2025, 36(1):30. https:\/\/doi.org\/10.1007\/s12022-025-09875-y","DOI":"10.1007\/s12022-025-09875-y"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Park SH, Sugier PE, Asgari Y, Karimi M, Kaaks R, Fortner RT, Schulze M, Agnoli C, Pasanisi F, Sacerdote C, Rodriguez-Barranco M, Aizpurua A, Cabrera Castro N, Guevara M, Tin Tin S, Weiderpass E, de Vathaire F, Lesueur F, Gu\u00e9nel P, Mulot C, Laurent-Puig P, Ostroumova E, Boland-Auge A, Deleuze JF, Thomsen H, F\u00f6rsti A, Elisei R, Gemignani F, Landi S, Rinaldi S, Elbaz A, Domenighetti C, Truong T. Reproductive factors, sex hormone levels, and differentiated thyroid cancer risk: a Mendelian randomization study. Thyroid, 2025, 35(4):433-443. https:\/\/doi.org\/10.1089\/thy.2024.0548","DOI":"10.1089\/thy.2024.0548"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Ezzat S, Pasternak JD, Rajaraman M, Abdel-Rahman O, Boucher A, Chau NG, Chen S, Gill S, Hyrcza MD, Lamond N, Massicotte MH, Winquist E, Mete O. Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma. Front Oncol, 2024, 14:1437360. https:\/\/doi.org\/10.3389\/fonc.2024.1437360","DOI":"10.3389\/fonc.2024.1437360"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Schipor S, Publik MA, Manda D, Ceausu M. Aggressive thyroid carcinomas clinical and molecular features: a systematic review. Int J Mol Sci, 2025, 26(12):5535. https:\/\/doi.org\/10.3390\/ijms26125535","DOI":"10.3390\/ijms26125535"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] Yamazaki H, Sugino K, Inoue K, Katoh R, Matsuzu K, Kitagawa W, Nagahama M, Saito A, Ito K. Analysis of immediate 503 thyroid carcinoma deaths: trend of single institution in 2005-2024. Eur Thyroid J, 2025, 14(2):e240368. https:\/\/doi.org\/10.1530\/ETJ-24-0368","DOI":"10.1530\/ETJ-24-0368"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Mitrica M, Vasiliu O, Plesa A, Sirbu OM. Multinodular and vacuolating neuronal tumor - challenges and perspectives. Rom J Mil Med, 2025, 128(1):10-16. https:\/\/doi.org\/10.55453\/rjmm.2025.128.1.2","DOI":"10.55453\/rjmm.2025.128.1.2"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"[24] Huang D, Zhang J, Zheng X, Gao M. Predictive value of hematologic parameters and clinicopathological features of poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma. Langenbecks Arch Surg, 2024, 409(1):241. https:\/\/doi.org\/10.1007\/s00423-024-03431-8","DOI":"10.1007\/s00423-024-03431-8"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Alam IS, Patel KN. Management of poorly differentiated thyroid cancer and differentiated high-grade thyroid carcinoma. Surg Clin North Am, 2024, 104(4):751-765. https:\/\/doi.org\/10.1016\/j.suc.2024.02.005","DOI":"10.1016\/j.suc.2024.02.005"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"[26] Violetis O, Konstantakou P, Spyroglou A, Xydakis A, Kekis PB, Tseleni S, Kolomodi D, Konstadoulakis M, Mastorakos G, Theochari M, Aller J, Alexandraki KI. The long journey towards personalized targeted therapy in poorly differentiated thyroid carcinoma (PDTC): a case report and systematic review. J Pers Med, 2024, 14(6):654. https:\/\/doi.org\/10.3390\/jpm14060654","DOI":"10.3390\/jpm14060654"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Maeda T, Kato H, Ando T, Kawaguchi M, Shibata H, Ogawa T, Noda Y, Hyodo F, Matsuo M. MRI features of histological subtypes of thyroid cancer in comparison with CT findings: differentiation between anaplastic, poorly differentiated, and papillary thyroid carcinoma. Jpn J Radiol, 2025, 43(2):210-218. https:\/\/doi.org\/10.1007\/s11604-024-01660-x","DOI":"10.1007\/s11604-024-01660-x"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Janu\u015b D, Kujdowicz M, Kiszka-Wi\u0142koj\u0107 A, Kaleta K, Taczanowska-Niemczuk A, Radli\u0144ski J, Mo\u017cd\u017ce\u0144 K, Nowak Z, G\u00f3recki W, Starzyk JB. Ultrasound and histopathological assessment of benign, borderline, and malignant thyroid tumors in pediatric patients: an illustrative review and literature overview. Front Endocrinol (Lausanne), 2025, 15:1481804. https:\/\/doi.org\/10.3389\/fendo.2024.1481804","DOI":"10.3389\/fendo.2024.1481804"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Kim JY, Myung JK, Kim S, Tae K, Choi YY, Lee SJ. Prognosis of poorly differentiated thyroid carcinoma: a systematic review and meta-analysis. Endocrinol Metab (Seoul), 2024, 39(4):590-602. https:\/\/doi.org\/10.10.3803\/EnM.2024.1927","DOI":"10.3803\/EnM.2024.1927"},{"key":"ref29","unstructured":"[30] Altena R, Nilsson M, Bergman V, Dahlberg J, Juhlin CC, Zedenius J. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer]. Lakartidningen, 2024, 121:23108."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"[31] Chiba T. Molecular pathology of thyroid tumors: essential points to comprehend regarding the latest WHO Classification. Biomedicines, 2024, 12(4):712. https:\/\/doi.org\/10.3390\/biomedicines12040712","DOI":"10.3390\/biomedicines12040712"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"[32] Gu H, Wang J, Ran W, Li G, Hu S, Zhao H, Wang X, Wang J. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma. J Pathol Clin Res, 2024, 10(2):e356. https:\/\/doi.org\/10.1002\/cjp2.356","DOI":"10.1002\/cjp2.356"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"[33] Chen Q, Yu X. Fine-needle aspiration cytologic diagnosis of intrathyroidal thymic carcinoma: a review of the literature. Diagn Cytopathol, 2025, 53(10):507-515. https:\/\/doi.org\/10.1002\/dc.70004","DOI":"10.1002\/dc.70004"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Calcaterra M, Sada A, Karslioglu-French E, Morariu EM, McCoy KL, Ramonell KM, Kurtom S, Ohori NP, Chiosea SI, Seethala RR, Carty SE, Nikiforova MN, Nikiforov YE, Yip L. Disease-specific and histological outcomes of preoperative TERT promoter mutation detected in isolation or in combination with other mutations in thyroid neoplasms. Thyroid, 2025, Aug 20. https:\/\/doi.org\/10.1177\/10507256251370304","DOI":"10.1177\/10507256251370304"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"[35] Schlegel LE, Brill-Edwards M, Wang ZX, McNair C, Gargano S, Cottrill E. Detection of PTEN mutations in fine needle aspiration biopsies of indeterminate thyroid nodules: impact on diagnosis and prognosis. Head Neck, 2025, 47(8):2145-2151. https:\/\/doi.org\/10.1002\/hed.28127","DOI":"10.1002\/hed.28127"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] Coleman H, Yiannakis C, Wright S, Hilmi OJ. Cutaneous tumour seeding following percutaneous sampling of a thyroid malignancy. J Laryngol Otol, 2025, 139(5):424-426. https:\/\/doi.org\/10.1017\/S0022215121000451","DOI":"10.1017\/S0022215121000451"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"[37] Seok J, Kim YH, Won JK, Hwangbo Y, Park SY, Ryu J. Anaplastic and poorly differentiated thyroid carcinomas at intervention sites: implications of track seeding and the importance of follow-up monitoring - report of two cases. Eur Arch Otorhinolaryngol, 2025, 282(6):3357-3361. https:\/\/doi.org\/10.1007\/s00405-025-09281-4","DOI":"10.1007\/s00405-025-09281-4"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"[38] Caldeira M, Canberk S, Macedo S, Melo M, M\u00e1ximo V, Soares P. Comparative analysis of follicular cell-derived thyroid carcinoma: assessing the impact of high-grade features in an advanced disease cohort. Virchows Arch, 2025, 486(6):1305-1315. https:\/\/doi.org\/10.1007\/s00428-025-04109-2","DOI":"10.1007\/s00428-025-04109-2"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"[39] Orlando G, Capella G, Vocino Trucco G, Vissio E, Metovic J, Maletta F, Volante M, Papotti M. Prognostic impact of fibrosclerotic changes in non-papillary, non-anaplastic, follicular cell-derived thyroid carcinomas. Virchows Arch, 2025. https:\/\/doi.org\/10.1007\/s00428-025-04028-2","DOI":"10.1007\/s00428-025-04028-2"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"[40] Shi XQ, Liu XT, Liu XH, Geng HW, Zhang Z, Wang WY, Chen X, Zhao X, Jue BL, Qin B, Liu PP. Phosphoglycerate kinase 1 as a potential prognostic biomarker in papillary thyroid carcinoma. Front Pharmacol, 2025, 16:1542159. https:\/\/doi.org\/10.3389\/fphar.2025.1542159","DOI":"10.3389\/fphar.2025.1542159"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"[41] Piermattei A, Migliara G, Feraco A, Bruno C, Cioni L, Zhang Q, Padial-Urtueta B, Merenda E, Fadda G, Raffaelli M, Larocca LM, Mule A, Pontecorvi A, Rossi ED. Evaluation of PD-L1, TERT promoter mutations, and BRAFV600E mutation in poorly differentiated, differentiated high grade thyroid carcinoma and anaplastic carcinoma of the thyroid: our institutional experience. Virchows Arch, 2025, Jun 7. https:\/\/doi.org\/10.1007\/s00428-025-04134-1","DOI":"10.1007\/s00428-025-04134-1"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"[42] Ghossein R, Instrum R, Dogan S, Chongtham N, Mullaney K, Roy D, Shaha A, Tuttle RM, Ganly I, Morris L, Xu B. Expanding the histologic spectrum of thyroid neoplasms with NTRK1\/2\/3 or ALK translocation: a single-center retrospective study of 82 cases. Virchows Arch, 2025, May 30. https:\/\/doi.org\/10.1007\/s00428-025-04133-2","DOI":"10.1007\/s00428-025-04133-2"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"[43] Perry WR, Giordano TJ. Update on somatic genomic alterations in follicular cell-derived thyroid cancers. Endocrinol Metab Clin North Am, 2025, 54(3):497-519. https:\/\/doi.org\/10.1016\/j.ecl.2025.03.017","DOI":"10.1016\/j.ecl.2025.03.017"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"[44] Feng J, Wu C, Shen F, Cai W, Xu B. Second primary differentiated thyroid carcinoma in adult cancer survivors: a SEER Database Analysis. J Clin Endocrinol Metab, 2025, 110(2):417-428. https:\/\/doi.org\/10.1210\/clinem\/dgae501","DOI":"10.1210\/clinem\/dgae501"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"[45] Sailaubekova Y, Matsuda K, Akazawa Y, Kurohama H, Matsuoka Y, Suzuki K, Kerimbayeva A, Kondo H, Nguyen VPT, Nguyen TNA, Nguyen TN, Satoh S, Shindo H, Yamashita H, Nakashima M. Altered expression of autophagy-related molecules and \u03b2-catenin in different subtypes of thyroid cancer: co-localization in intranuclear cytoplasmic inclusions. Endocr J, 2025, Jul 17:EJ25-0181. https:\/\/doi.org\/10.1507\/endocrj.EJ25-0181","DOI":"10.1507\/endocrj.EJ25-0181"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"[46] Moretti S, Mandarano M, Menicali E, Guzzetti M, Morelli S, Talpacci E, Colella R, Bini V, Giannini R, Ugolini C, Sidoni A, Basolo F, Puxeddu E. Wnt\/\u03b2-catenin activation and TP53 mutations associate with distinct immune profiles in advanced thyroid cancer. J Clin Endocrinol Metab, 2025, 110(4):1003-1014. https:\/\/doi.org\/10.1210\/clinem\/dgae667","DOI":"10.1210\/clinem\/dgae667"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"[47] Novis E, Glover A, Grady JP, Silvestri A, Thavaneswaran S, Lin F, Ballinger ML, Thomas DM. Oncogenic mutations in the TP53 and PI-3 kinase\/AKT pathway are independent predictors of survival for advanced thyroid cancer: analysis from the Molecular Screening and Therapeutics (MoST) program. Surgery, 2025, 177:108858. https:\/\/doi.org\/10.1016\/j.surg.2024.05.058","DOI":"10.1016\/j.surg.2024.05.058"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"[48] Bella Burgos B, Carrera Salas R, Onieva Carbajo R, Padilla Navas C, Ramos Guijo MDC, Escudero Larr\u00e1 L, Rodr\u00edguez Mill\u00e1n RM, V\u00e1zquez Luque JA, Hurtado Mas S, Asensi Puig A, Bl\u00e1zquez Ma\u00f1\u00e1 CM, Barcons Vilaplana S, Capel Flores I, Guirao Garriga X, P\u00e9rez-Riverola V, Moreno MP, Combalia Soriano N, Orellana Fern\u00e1ndez R, Ferreres Pi\u00f1as JC, Bella-Cueto MR. Study of the C228T mutation of the TERT promoter in thyroid aspirative punctures of IV category of the Bethesda classification. Endocrinol Diabetes Nutr (Engl Ed), 2025, 72(5):501564. https:\/\/doi.org\/10.1016\/j.endien.2025.501564","DOI":"10.1016\/j.endien.2025.501564"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"[49] Sara GB, Noa FR, Enrique PR, Miriam CG, Joaqu\u00edn FR, Ginesa GR. TERT amplification a risk stratification marker in papillary thyroid carcinoma, significantly correlated with tumor recurrence and survival. Endocr Pathol, 2025, 36(1):15. https:\/\/doi.org\/10.1007\/s12022-025-09853-4","DOI":"10.1007\/s12022-025-09853-4"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"[50] Pan Z, Tan Z, Xu N, Yao Z, Zheng C, Shang J, Xie L, Xu J, Wang J, Jiang L, Zhu X, Yu D, Li Y, Che Y, Gong Y, Qin Z, Zhang Y, Zou X, Xu T, Guo Z, Jin T, Guo T, Wang W, Chen W, Sun Y, Wang W, Peng X, Yin C, Ding C, Huang P, Ge M. Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers. Nat Commun, 2025, 16(1):3601. https:\/\/doi.org\/10.1038\/s41467-025-58910-3","DOI":"10.1038\/s41467-025-58910-3"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"[51] Hassan FA, Slone C, McDonald RJ, Dueber JC, Ashraf AM, Windon MJ, Fackelmayer OJ, Lee CY, Bocklage TJ, Allison DB. Folliculin (FLCN) in thyroid tumors: incidence, significance, and role as a driver gene and secondary alteration. Curr Oncol, 2025, 32(4):224. https:\/\/doi.org\/10.3390\/curroncol32040224","DOI":"10.3390\/curroncol32040224"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"[52] Wijewardene A, Clifton-Bligh RJ, Wang B, Luxford C, Robinson BG, Bullock M, Gild M. Evaluating the prognostic potential of circulating cell-free DNA in advanced thyroid cancer. Endocr Relat Cancer, 2025, 32(2):e240227. https:\/\/doi.org\/10.1530\/ERC-24-0227","DOI":"10.1530\/ERC-24-0227"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"[53] Nervo A, Ferrari M, Vaccaro E, Migliore E, Gruosso G, Roux A, Piovesan A, Arvat E. Tailored management of advanced thyroid cancer patients treated with Lenvatinib or Vandetanib: the role of a multimodal approach. Endocrine, 2025, 87(2):724-733. https:\/\/doi.org\/10.1007\/s12020-024-04061-2","DOI":"10.1007\/s12020-024-04061-2"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"[54] Benson P, Abdel-Rahman O. Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer. Immunotherapy, 2025, 17(1):47-55. https:\/\/doi.org\/10.1080\/1750743X.2025.2455922","DOI":"10.1080\/1750743X.2025.2455922"},{"key":"ref54","unstructured":"[55] Dumitru N, Carsote M, Cocolos A, Petrova E, Olaru M, Dumitrache C, Ghemigian A. The link between bone osteocalcin and energy metabolism in a group of postmenopausal women. Curr Health Sci J, 2019, 45(1):47-51. https:\/\/doi.org\/10.12865\/CHSJ.45.01.06"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"[56] Song P, Pan G, Zhang Y, Ni Y, Wang Q, Shi J, Peng Y, Jing R, Luo D. Prospects and challenges of immunotherapy for thyroid cancer. Endocr Pract, 2025, 31(3):373-379. https:\/\/doi.org\/10.1016\/j.eprac.2024.11.012","DOI":"10.1016\/j.eprac.2024.11.012"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"[57] Regala C, Silva TN, Leite V. The role of Lenvatinib in different types of thyroid cancer. Minerva Endocrinol (Torino), 2025, Jul 30. https:\/\/doi.org\/10.23736\/S2724-6507.25.04309-X","DOI":"10.23736\/S2724-6507.25.04309-X"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"[58] Ruicci KM, Deng Y, Xiao T, Eskander A, Goldstein D, Mete O, Mesci A, Lukovic J, Krzyzanowska MK, Barron CC, Ma LX. Real-world treatment outcomes and clinicopathologic and molecular determinants of response to first-line Lenvatinib in patients with advanced follicular cell-derived thyroid cancer. BJC Rep, 2025, 3(1):41. https:\/\/doi.org\/10.1038\/s44276-025-00153-2","DOI":"10.1038\/s44276-025-00153-2"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"[59] Califano I, Randolph G, Pitoia F. Transforming thyroid cancer management: the impact of neoadjuvant therapy. Endocr Relat Cancer, 2025, 32(4):e240185. https:\/\/doi.org\/10.1530\/ERC-24-0185","DOI":"10.1530\/ERC-24-0185"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"[60] Xu LF, Shi N, Niu JL, An N, Xi YQ, Huang QY, Jiang L, Chen J. Neoadjuvant treatment in locally advanced thyroid cancer: a single institution experience. Front Oncol, 2025, 15:1590086. https:\/\/doi.org\/10.3389\/fonc.2025.1590086","DOI":"10.3389\/fonc.2025.1590086"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"[61] Dagher SA, Learned KO, Dagher R, Wang JR, Zhao X, Hosseini SM, Maniakas A, Cabanillas ME, Busaidy NL, Dadu R, Iyer P, Zafereo ME, Khalaf AM. [18F]-FDG uptake as a marker of residual anaplastic and poorly differentiated thyroid carcinoma following BRAF-targeted therapy. AJNR Am J Neuroradiol, 2025, 46(6):1260-1267. https:\/\/doi.org\/10.3174\/ajnr.A8588","DOI":"10.3174\/ajnr.A8588"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"[62] Lee KK, Morris JC 3rd, Kumar A, Chintakuntlawar AV, Peskey C, Hilger CR, Bible KC, Ryder M. Pemetrexed-Carboplatin salvage therapy in advanced thyroid cancers. Head Neck, 2025, 47(3):813-821. https:\/\/doi.org\/10.1002\/hed.27940","DOI":"10.1002\/hed.27940"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"[63] Jonker PKC, Koetje JH, Turchini J, Lin JFA, Gill AJ, Eade T, Aniss A, Clifton-Bligh R, van Hemel BM, Learoyd D, Verbeek HHG, Links TP, Robinson B, Tsang V, Sidhu S, Kruijff S, Sywak MS. Adjuvant external beam radiotherapy reduces local recurrence in poorly differentiated thyroid cancer: a multicenter retrospective cohort study describing outcomes in the treatment of resectable poorly differentiated thyroid cancer. Ann Surg Oncol, 2025, 32(9):6752-6764. https:\/\/doi.org\/10.1245\/s10434-025-17434-2","DOI":"10.1245\/s10434-025-17434-2"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"[64] Radi S, Al-Maghrabi M, Binmahfooz S, Franco M, Payne R, Tamilia M. Characteristics and prognostic markers of aggressive subtypes of thyroid cancer: a retrospective study. Cancer Rep (Hoboken), 2025, 8(3):e70131. https:\/\/doi.org\/10.1002\/cnr2.70131","DOI":"10.1002\/cnr2.70131"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"[65] Marczyk VR, Fazeli S, Dadu R, Busaidy NL, Iyer P, Hu MI, Sherman SI, Hamidi S, Hosseini SM, Williams MD, Ahmed S, Routbort MJ, Luthra R, Roy-Chowdhuri S, San Lucas FA, Patel KP, Hong DS, Zafereo M, Wang JR, Maniakas A, Waguespack SG, Cabanillas ME. NTRK fusion-positive thyroid carcinoma: from diagnosis to targeted therapy. JCO Precis Oncol, 2025, 9:e2400321. https:\/\/doi.org\/10.1200\/PO.24.00321","DOI":"10.1200\/PO.24.00321"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"[66] Wang P, Hou X, Sun W, Chen J, Cao Y, Cheng H. miR-590-5p mediates mitochondrial respiration, proliferation, and apoptosis in thyroid carcinoma cells via fibroblast growth factor receptor substrate 2. Arch Endocrinol Metab, 2025, 69(4):e240410. https:\/\/doi.org\/10.20945\/2359-4292-2024-0410","DOI":"10.20945\/2359-4292-2024-0410"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"[67] Guo K, Yang L, Huang Z, Qian K, Shi Y, Fei M, Feng Y, Chen Z, Qiu M, Tang L, Li A, Lv Z, Liu J, Chen Z, Dong K, Wang Z. Single-cell RNA sequencing reveals the heterogeneity in differentiation trajectory and tumor microenvironment leading to more aggressive phenotypes of papillary thyroid cancer in children and young adult patients. Adv Sci (Weinh), 2025, Jul 28:e17672. https:\/\/doi.org\/10.1002\/advs.202417672","DOI":"10.1002\/advs.202417672"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"[68] Alnwisser B, Alshehri S, Qattan A, Zou M, Aboussekhra A, Alzahrani AS, Shi Y. Identification of novel prognostic biomarkers for thyroid cancer by integrated transcriptome analysis of metastasis-associated genes. Front Oncol, 2025, 15:1536270. https:\/\/doi.org\/10.3389\/fonc.2025.1536270","DOI":"10.3389\/fonc.2025.1536270"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"[69] Zhu L, Jing X, Ahn BC. Turning tumor microenvironmental foes to friends: a new opportunity for thyroid cancer therapy and redifferentiation. Oral Oncol, 2025, 168:107513. https:\/\/doi.org\/10.1016\/j.oraloncology.2025.107513","DOI":"10.1016\/j.oraloncology.2025.107513"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"[70] Lin B, Jiang X, Bhandari A, Chen Q, Pan Y. FAM20C promotes papillary thyroid cancer proliferation and metastasis via epithelial-mesenchymal transition. Mol Carcinog, 2025, 64(1):152-161. https:\/\/doi.org\/10.1002\/mc.23833","DOI":"10.1002\/mc.23833"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"[71] Ye J, Chen L. Current landscape of hypoxia in thyroid cancer pathogenesis and treatment. Crit Rev Oncol Hematol, 2025, 211:104719. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104719","DOI":"10.1016\/j.critrevonc.2025.104719"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"[72] Rustad JL, Gillis NE, Lignos J, Bright KA, Frietze S, Carr FE. Epigenomic modulators and thyroid hormone receptor \u03b2 agonists: a new paradigm for tumor suppression in thyroid cancer. Endocrinology, 2025, 166(9):bqaf116. https:\/\/doi.org\/10.1210\/endocr\/bqaf116","DOI":"10.1210\/endocr\/bqaf116"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"[73] Sanchis-Pascual D, Del Olmo-Garc\u00eda MI, Morillas-Amat P, Prado-Wohlwend S, Segura Huerta \u00c1, Merino-Torres JF. Epigenetic mechanisms in neuroendocrine neoplasms: is there a place for inhibitors of DNA binding proteins? Front Biosci (Landmark Ed), 2025, 30(6):26581. https:\/\/doi.org\/10.31083\/FBL26581","DOI":"10.31083\/FBL26581"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"[74] Wang IE, SaTsu HA, Brooks AF, Werner RA, Rowe SP, Scott PJH, Viglianti BL. Molecular imaging of neuroendocrine tumors: current applications and future trends. Diagn Interv Imaging, 2025, May 21:S2211-S5684(25)00103-2. https:\/\/doi.org\/10.1016\/j.diii.2025.05.005","DOI":"10.1016\/j.diii.2025.05.005"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"[75] Rios-Morris E, Tientcheu Ngaffi VI, Costagliola S, Romitti M. Novel insights in advanced thyroid carcinoma: from mechanisms to treatments: development of 3D organoid models to study aggressive thyroid cancers. Eur Thyroid J, 2025, 14(4):e240392. https:\/\/doi.org\/10.1530\/ETJ-24-0392","DOI":"10.1530\/ETJ-24-0392"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"[76] Zou M, Qattan A, Al-Alwan M, Ghebeh H, Binjumah N, Al-Haj L, Khabar KSA, Altaweel A, Almohanna F, Assiri AM, Aboussekhra A, Alzahrani AS, Shi Y. Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis. Front Endocrinol (Lausanne), 2025, 16:1514264. https:\/\/doi.org\/10.3389\/fendo.2025.1514264","DOI":"10.3389\/fendo.2025.1514264"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"[77] Tran MT, Monroe HL, Ozolek JA, El Naili R. DICER1 mutation-associated follicular thyroid tumor with bizarre and pleomorphic nuclei. Cureus, 2025, 17(5):e83644. https:\/\/doi.org\/10.7759\/cureus.83644","DOI":"10.7759\/cureus.83644"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"[78] Popa FL, Boicean LC, Iliescu MG, Stanciu M. The importance of association between sex steroids deficiency, reduction of bone mineral density and falling risk in men with implications in medical rehabilitation. Balneo PRM Res J, 2021, 12(4):318-322. https:\/\/doi.org\/10.12680\/balneo.2021.457","DOI":"10.12680\/balneo.2021.457"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"[79] Schiavo Lena M, S\u00e1nchez-Ares M, Brunetto E, Abdulkader-Nallib I, Maggiore R, Barbieri D, Vigone MC, Perticone F, Lanzi R, Presi S, Carrera P, Cangi MG, Arrigoni G, Doglioni C, Cameselle-Teijeiro JM. Focal high-grade areas with a tumor-in-tumor pattern: another feature of pediatric DICER1-associated thyroid carcinoma? Endocr Pathol, 2025, 36(1):20. https:\/\/doi.org\/10.1007\/s12022-025-09863-2","DOI":"10.1007\/s12022-025-09863-2"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"[80] Mosoane B, McCabe M, Jackson BS, Dlamini Z. CD44 variant expression in follicular cell-derived thyroid cancers: implications for overcoming multidrug resistance. Molecules, 2025, 30(9):1899. https:\/\/doi.org\/10.3390\/molecules30091899","DOI":"10.3390\/molecules30091899"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"[81] Huang J, Wang J, Wang G, Zhao Y. Allele frequency in thyroid cancer: mechanisms, challenges, and applications in cancer therapy. Thyroid Res, 2025, 18(1):19. https:\/\/doi.org\/10.1186\/s13044-025-00237-8","DOI":"10.1186\/s13044-025-00237-8"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"[82] Lan Y, Liu D, Liang B, Song X, Xie L, Peng H, Guo H, Hong C, Weng X, Wei X, Liao X, Liang R, Huang D, Liu M. ITGA3-MET interaction promotes papillary thyroid cancer progression via ERK and PI3K\/AKT pathways. Ann Med, 2025, 57(1):2483379. https:\/\/doi.org\/10.1080\/07853890.2025.2483379","DOI":"10.1080\/07853890.2025.2483379"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"[83] Picello L, Dalle Nogare M, Puggina D, Salvoro C, Pennelli G, Gaudenzi G, Carra S, Oldani M, Gentilini D, Fugazzola L, Faggiano A, Vitale G, Occhi G, Vazza G. Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma. Endocr Relat Cancer, 2025, 32(5):e240344. https:\/\/doi.org\/10.1530\/ERC-24-0344","DOI":"10.1530\/ERC-24-0344"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"[84] Van Branteghem C, Henry N, Craciun L, Maenhaut C. HMGA2 overexpression in papillary thyroid cancer promotes thyroid cell dedifferentiation and invasion, and these effects are counteracted by Suramin. Int J Mol Sci, 2025, 26(4):1643. https:\/\/doi.org\/10.3390\/ijms26041643","DOI":"10.3390\/ijms26041643"},{"key":"ref84","unstructured":"[85] Valea A, Carsote M, Moldovan C, Georgescu C. Chronic autoimmune thyroiditis and obesity. Arch Balk Med Union, 2018, 53(1):64-69."},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"[86] Du X, Chen W. Bioinformatic analysis of serpina1 expression in papillary thyroid carcinoma and its potential association with Hashimoto's thyroiditis. Discov Oncol, 2025, 16(1):356. https:\/\/doi.org\/10.1007\/s12672-025-02079-0","DOI":"10.1007\/s12672-025-02079-0"},{"key":"ref86","unstructured":"[87] Valea A, Ghervan C, Morar A, Pop DD, Carsote M, Albu SE, Georgescu CE, Chiorean A. Hashimoto's thyroiditis and breast cancer: coincidence or correlation? Arch Balk Med Union, 2016, 51(1):125-128."},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"[88] Wei S, Baloch ZW, LiVolsi VA. Thyroid carcinoma in patients with Graves' disease: an institutional experience. Endocr Pathol, 2015, 26(1):48-53. https:\/\/doi.org\/10.1007\/s12022-014-9343-6","DOI":"10.1007\/s12022-014-9343-6"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"[89] Pagano L, Mele C, Sama MT, Zavattaro M, Caputo M, De Marchi L, Paggi S, Prodam F, Aimaretti G, Marzullo P. Thyroid cancer phenotypes in relation to inflammation and autoimmunity. Front Biosci (Landmark Ed), 2018, 23(12):2267-2282. https:\/\/doi.org\/10.2741\/4705\"","DOI":"10.2741\/4705"}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"link":[{"URL":"https:\/\/rjme.ro\/RJME\/resources\/files\/660325431442.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:45:09Z","timestamp":1768819509000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/66\/3\/1\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":89,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2025,12,12]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.66.3.01","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}